
What is claimed:

1. A pharmaceutical composition comprising:

a solid dispersion, wherein the solid dispersion comprises:

a compound represented by:



or a pharmaceutically acceptable salt thereof, and

a polymer;

wherein the solid dispersion comprises 10 wt % to 50 wt % of the compound, or a pharmaceutically acceptable salt thereof, and 40 wt % to 90 wt % of the polymer.

2. The pharmaceutical composition of claim 1, wherein the solid dispersion comprises 15 wt % to 30 wt % of compound, or a pharmaceutically acceptable salt thereof, and 70 wt % to 90 wt % of the polymer.

3. The pharmaceutical composition of claim 1 or 2, wherein the polymer is a methacrylate polymer or a cellulosic polymer.

4. The pharmaceutical composition of any one of claims 1-3, wherein the polymer is selected from the group consisting of poly(methacrylic acid-co-methyl methacrylate), hypromellose acetate succinate, and hydroxypropyl methylcellulose phthalate.

5. The pharmaceutical composition of any one of claims 1-4, wherein the solid dispersion is a spray-dried solid dispersion.

6. The pharmaceutical composition of any one of claims 1-5, wherein the solid dispersion is a substantially amorphous solid dispersion.

7. The pharmaceutical composition of any one of claims 1-5, wherein the solid dispersion is an amorphous solid dispersion.

8. The pharmaceutical composition of claim 6 or 7, wherein the solid dispersion has a single T_g.

9. The pharmaceutical composition of claim 8, wherein the solid dispersion is stable for at least four weeks.

10. The pharmaceutical composition of any one of claims 1-9, wherein the pharmaceutical composition further comprises an excipient.

11. The pharmaceutical composition of claims 10, wherein the solid dispersion further comprises an excipient.

12. The pharmaceutical composition of claim 10 or 11, wherein the excipient is selected from the group consisting of a filler, a sweetener, diluent, binder, lubricant, disintegrant, and glidant.

13. The pharmaceutical composition of claim 10 or 11, wherein the excipient is selected from the group consisting of microcrystalline cellulose, mannitol, talc, croscarmellose sodium, magnesium stearate, and sodium lauryl sulfate.

14. The pharmaceutical composition of claim 10 or 11, wherein the pharmaceutical composition further comprises a colorant, a fragrance, or flavoring agent.

15. The pharmaceutical composition of any one of claims 1-14, wherein the pharmaceutical composition is in a dose form selected from the group consisting of a granule, a pellet, a tablet, a particle, and a mini-tablet.

16. The pharmaceutical composition of any one of claims 1-15, wherein the pharmaceutical composition comprises a pharmaceutically effective amount of the compound or a pharmaceutically acceptable salt thereof.

17. The pharmaceutical composition of any one of claims 1-16, wherein the pharmaceutical composition is in a dose form comprising 75 mg to 125 mg of the compound, or a pharmaceutically acceptable salt thereof.

18. Use of a pharmaceutical composition according to any one of claims 1-17 in the manufacture of a medicament for treating Hepatitis B (HBV) in a patient in need thereof, wherein a therapeutically effective amount of the pharmaceutical composition is to be administered to the patient.

19. A method for preparing a pharmaceutical composition, the method comprising:

combining 11-oxo-N-((2-(trifluoromethyl)thiazol-5-yl)methyl)-10,11-dihydrodibenzo[b,f][1,4]thiazepine-8-carboxamide 5,5-dioxide, or a pharmaceutically acceptable salt thereof, and a polymer in a solvent thereby forming a mixture,

drying the mixture thereby forming a solid dispersion; and

optionally combining the solid dispersion with an excipient.

20. The method of claim 19, wherein drying the mixture comprises spray drying the mixture.

21. The method of claim 19 or 20, wherein the solvent comprises water.

22. The method of any one of claims 19-21, wherein the solvent comprises an organic solvent.

23. The method of any one of claims 19-22, wherein the solvent comprises acetone and water.

24. The method of any one of claims 19-23, wherein the polymer is selected from the group consisting of poly(methacrylic acid-co-methyl methacrylate), hypromellose acetate succinate, and hydroxypropyl methylcellulose phthalate.

25. The method of any one of claims 19-24, wherein the solid dispersion is a substantially amorphous solid dispersion ion.

26. The method of any one of claims 19-24, wherein the solid dispersion is an amorphous solid dispersion.

27. The method of claim 25 or 26, wherein the solid dispersion has a single T_g.

28. The method of any one of claims 19-27, wherein the excipient is selected from the group consisting of a filler, sweetener, diluent, binder, lubricant, disintegrant, and glidant.

29. The method of any one of claims 18-26, wherein the excipient is selected from the group consisting of microcrystalline cellulose, mannitol, talc, croscarmellose sodium, magnesium stearate, and sodium lauryl sulfate.

30. The method of any one of claims 19-29, wherein the solid dispersion comprises 10 wt % to 50 wt % of 11-oxo-N-((2-(trifluoromethyl)thiazol-5-yl)methyl)-10,11-dihydrodibenzo[b,f][1,4]thiazepine-8-carboxamide 5,5-dioxide, or a pharmaceutically acceptable salt thereof, and 40 wt % to 90 wt % of the polymer.

31. The method of any one of claims 19-29, wherein the solid dispersion comprises 15 wt % to 30 wt % of 11-oxo-N-((2-(trifluoromethyl)thiazol-5-yl)methyl)-10,11-dihydrodibenzo[b,f][1,4]thiazepine-8-carboxamide 5,5-dioxide, or a pharmaceutically acceptable salt thereof, and 70 wt % to 90 wt % of the polymer.

32. The method of any one of claims 19-31, further comprising: compressing the pharmaceutical composition into a tablet.